Shots:

• The P-III ALTA-1L study involves assessing of Alunbrig (180mg- qd for 7days lead in 90mg qd) vs Crizotinib (250mg- bid) in 275 patients with anaplastic lymphoma kinase-positive (ALK+) LA/ metastatic NSCLC- prior not treated with an ALK inhibitor
• Following 2yrs. follow up- 76% & 57% reduction in disease progression in newly diagnosed & in all patients. Additionally- mPFS in patients with brain metastases (not reached vs 5.6mos.); intracranial ORR (78% vs 26%); intracranial DOR (not reached vs 9.2mos.)- efficacy with follow up of 25mos.- mPFS (29.4 vs 9.2mos.); ORR (74% vs 62%); mDOR (not reached vs 13.8mos.)
• Alunbrig is a potent and selective TKI inhibitor- designed to target and inhibit ALK fusion protein in NSCLC and has received the US FDA’s accelerated approval in Apr’2017

Click here to­ read full press release/ article 

 Ref: Takeda  | Image: Takeda